Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
RestoreD
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
Breve descripción
The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN2050) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.
Médico del ensayo/Coordinador del estudio
Valdivia Guillermo
Correo electrónicoNombre del sitio
University of New Mexico
1 University of New Mexico, Albuquerque, NM 87131
Nombre del patrocinador
Alexion Pharmaceuticals, Inc.
Nombre del fármaco del estudio
ALXN2050
Matrícula estimada
126
Fecha estimada de finalización
08-24-2026
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
RestoreD
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
Breve descripción
The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN2050) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.
El ensayo es para personas con
Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
Objetivo del estudio
This randomized placebo-controlled dose-finding study is to evaluate the safety and efficacy of ALXN2050 in adult participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN).
Qué implica para el paciente?
This study will include 126 participants (56 IgAN and 70 LN). The total study duration for each participant will be approximately 3 years. If you qualify and decide to participate in this study, you will be assigned by chance (randomly) to receive ALXN2050 180 mg, or ALXN2050 120 mg, or placebo as oral tablets. The placebo tablet looks like ALXN2050 but does not contain the active ingredient. You will be asked to undergo a number of procedures at your study visits. Before you choose to participate, you should speak with your doctor.
Sobre el medicamento o la intervención
The study drug (ALXN2050) is an oral tablet.